---
title: Detect thinking decline using recordings
nct_id: NCT06640673
status: RECRUITING
sponsor: IRCCS San Camillo, Venezia, Italy
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06640673"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06640673"
last_fetched: "2026-05-10T14:05:48.716Z"
source: "Parkinson's Pathways (curated)"
---
# Detect thinking decline using recordings

**Goal (in five words):** Detect thinking decline using recordings

**Official Title:** Electrophysiological Signature of Mild Cognitive Impairment and Its Relationship with Parkinson's Disease: a High-density EEG Investigation

**Trial ID:** [NCT06640673](https://clinicaltrials.gov/study/NCT06640673)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** IRCCS San Camillo, Venezia, Italy
- **Target Enrollment:** 42 participants
- **Start Date:** 2023-06-18
- **Completion Date:** 2024-12-01
- **Conditions:** Parkinson Disease, Parkinson Disease, Mild Cognitive Impairment, Healthy
- **Interventions:** Hd-EEG
- **Intervention Types:** DIAGNOSTIC_TEST

## Summary For Families

The team wants to identify an electrical brain signature that marks mild cognitive impairment in people with Parkinson's and to compare those signals with healthy aging. They will record high-density EEG, which maps brain electrical rhythms across many scalp sites to detect subtle slowing or connectivity changes, and because the work is observational it does not change treatment so participants may be taking stable doses of levodopa, antidepressants, or cholinesterase drugs. They are enrolling adults 50 to 90 who can walk independently, who do not have severe dementia and have relatively preserved cognition on screening (MMSE >24 or MoCA >15.5), with any Parkinson's or related medications kept stable for at least four weeks.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 90 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Upper score \>24 MMSE or \>15.5 Moca
* If taking medications, taking stable doses for at least 4 weeks prior to the inclusion visit - of anticholinesterase drugs (donepezil, memantine, rivastigmine, ...) or antidepressants (SSRIs, tricyclics, SNARI, ...) or Levodopa.
* Having signed the informed consent

Exclusion Criteria:

* Subjects with severe dementia ( MMSE \< 24 )
* Lower score \<15.5 Moca
* Subjects on antipsychotic treatment for less than 3 months
* Subjects with uncontrolled comorbidities
* Subjects with metal prostheses or dentures and in general conditions for which MRI examinations are prevented.
* Subjects with an inability to walk independently.
```

## Locations (1)

- IRCCS San Camillo S.R.L, Lido, Italy, Italy _(45.4105, 12.3665)_
  - Francesca Burgio — (CONTACT) — +39 0412207536 — francesca.burgio@hsancamillo.it
  - Giovanni Lazzaro — (CONTACT) — 04122079598 — giovanni.lazzaro@hsancamillo.it

## Central Contacts

- Francesca Burgio, PhD — (CONTACT) — +390412207536 — francesca.burgio@hsancamillo.it
- Giovanni Lazzaro, MSc — (CONTACT) — +3904122079598 — giovanni.lazzaro@hsancamillo.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06640673*  
*HTML version: https://parkinsonspathways.com/trial/NCT06640673*  
*Source data: https://clinicaltrials.gov/study/NCT06640673*